Ligand Pharma (LGND) Tops Q3 EPS by 6c, Offers FY20 and FY21 Guidance

Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $1.04, $0.06 better than the analyst estimate of $0.98. Revenue for the quarter came in at $41.8 million versus the consensus estimate of $44.36 million.

GUIDANCE:

Ligand Pharma sees FY2020 EPS of $3.95, versus the consensus of $3.91. Ligand Pharma sees FY2020 revenue of $170 million, versus the consensus of $170.2 million.

Ligand Pharma sees FY2021 EPS of $6.00, versus the consensus of $5.89. Ligand Pharma sees FY2021 revenue of $285 million, versus the consensus of $277 million.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• American Express (AXP) Tops Q3 EPS by 84c, Misses on Revenue, Raises FY Guidance
• SLM (SLM) Misses Q3 EPS by 36c; lowers guidance
• Gorman-Rupp (GRC) Tops Q3 EPS by 16c, Beats on Revenue